Kin­nate lays off 70% of em­ploy­ees, shaves pipeline to fo­cus on CDK4 and pan-RAF in­hibitor

Kin­nate Bio­phar­ma has re­duced its em­ploy­ee head­count by 70% — leav­ing just 28 full-time em­ploy­ees — and is “sep­a­rat­ing” from all em­ploy­ees at its Chi­nese sub­sidiary, Kin­njiu Bio­phar­ma, as part of cost-sav­ing mea­sures to ex­tend its cash run­way in­to at least the sec­ond quar­ter of 2026.

The Cal­i­for­nia-head­quar­tered can­cer com­pa­ny is al­so chang­ing up its pipeline, fo­cus­ing on its exarafenib/binime­tinib com­bo, KIN-8741, and its CDK4 se­lec­tive pro­gram. For now, Kin­nate will halt de­vel­op­ment of MEK in­hibitor KIN-7136, and “ex­plore strate­gic al­ter­na­tives” for its exarafenib monother­a­py and FGFR in­hibitor KIN-3248.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.